In India's medical device regulatory landscape, a brand name plays an important role in product identification, market differentiation, regulatory documentation, and post-market traceability. The Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare, regulates medical devices under the Medical Devices Rules, 2017 (MDR 2017).
Changing the brand name of an approved medical device should not be treated as a simple commercial or administrative update. Depending on the nature of the change and its impact on approved product information and labelling, the licence holder may be required to follow the applicable post-approval change (PAC) procedure prescribed under MDR 2017 and current CDSCO requirements.
A medical device's brand name is an important element of its commercial and regulatory identity. During regulatory submissions, product information may include the device name, model details, intended use, labelling, and other identifying particulars.
For medical devices marketed in India, approved product information and labelling support several important regulatory functions, including:
A change in brand name may consequently affect several controlled documents and materials, including product labels, packaging, Instructions for Use (IFU), technical documentation, promotional literature, and post-market surveillance records.
Therefore, before implementing a new brand name or introducing an additional brand name, manufacturers and authorised agents should assess the applicable CDSCO regulatory requirements.
The Medical Devices Rules, 2017 provide a framework for managing changes made after the grant of a manufacturing or import licence.
The Sixth Schedule to MDR 2017 categorises certain post-approval changes as either major or minor changes.
In general:
Changes involving approved product labelling require particular attention. The Sixth Schedule identifies substantive changes to labels, other than certain limited changes such as font size, font type, colour, or label design, within the major change framework.
Since a brand name may form part of the product's approved identity and labelling, a proposed brand name change should be carefully assessed under the applicable PAC provisions.
CDSCO's operational processes and guidance have also included regulatory pathways for matters relating to additional brand names. Therefore, companies should not assume that a new or additional brand name can be introduced without regulatory assessment.
The exact pathway may depend on factors such as:
A brand name update may affect more than the commercial identity of a product. It can also result in changes to regulatory documents and approved labelling.
Depending on the circumstances, related changes may include:
Other changes that may require separate regulatory assessment include:
It is important to distinguish a pure brand-related change from other changes that may affect the device itself. If a brand name change is accompanied by changes to the product design, intended purpose, manufacturing process, specifications, or performance, additional regulatory requirements may apply.
Before initiating the change, the licence holder should conduct an internal regulatory and quality assessment.
The assessment should determine:
A documented change-control assessment is recommended to establish the rationale for the proposed modification and its regulatory impact.
The exact documentation required may vary depending on the applicable PAC category, type of device, licence route, and current CDSCO portal requirements.
Depending on the nature of the proposed change, supporting documentation may include:
All submitted information should remain consistent across the application, labels, technical documentation, and supporting regulatory records.
Post-approval change applications are generally processed through the applicable CDSCO online system or relevant regulatory portal.
The applicant should:
Where an additional brand name or related product identity change is proposed, applicants should carefully review the available portal categories and current CDSCO instructions before submission.
For devices regulated by State Licensing Authorities, the applicable State-level procedures should also be considered.
The applicable review process and timelines may vary depending on:
The Medical Devices Rules, 2017 prescribe specific licence conditions and procedures for post-approval changes. Applicants should verify the currently applicable provisions and CDSCO operational requirements before relying on any specific timeline.
As a general compliance principle, companies should avoid implementing a substantive change affecting approved product identity or labelling until the applicable regulatory process has been completed and the necessary approval or regulatory clearance has been obtained in accordance with MDR 2017.
Once the applicable regulatory process has been completed, the new or additional brand name should be implemented consistently across all relevant documents and systems.
This may include updates to:
Consistency is essential to maintain product traceability and avoid confusion between previously marketed and newly branded products.
All labelling must continue to comply with applicable requirements under MDR 2017, including Rule 46 and relevant schedules.
Companies should also assess obligations under other applicable laws, including trademark and legal metrology requirements where relevant.
The applicable regulatory fee should be verified based on:
CDSCO guidance has addressed situations involving multiple brand names, and applicable product fees may be relevant for each brand name depending on the specific application pathway.
Applicants should therefore verify the latest requirements under the Second Schedule of MDR 2017 and the current CDSCO portal before submitting an application.
A change in the constitution of the licence holder is different from a change in the brand name of a product.
Changes involving the legal constitution of the licence holder may trigger separate regulatory obligations under MDR 2017.
A brand name modification alone does not necessarily constitute a change in the legal constitution of the manufacturer, importer, or licence holder. However, where a brand-related transaction is connected to a merger, acquisition, transfer of ownership, or change in the legal entity, additional regulatory assessment may be required.
For imported medical devices, the authorised agent should ensure that the proposed change remains consistent with applicable overseas manufacturer documentation and Indian regulatory submissions.
Depending on the nature of the change, CDSCO may require supporting information relating to:
Foreign manufacturers should not assume that a brand name used exclusively in India can automatically be introduced without assessing applicable CDSCO requirements.
Changes to model names or model numbers should be assessed separately from brand name changes.
Although these changes may be commercially connected, they can have different implications for product identification and regulatory documentation.
Where multiple changes are proposed simultaneously, the applicant should clearly explain each modification and its impact on the approved device.
Private labelling and the marketing of technically similar or identical devices under multiple brand names can create additional regulatory complexities.
These arrangements may require assessment of:
Professional regulatory advice is recommended where the same device is proposed to be marketed under multiple brands or by different commercial entities.
The regulatory principles relating to post-approval changes apply across medical device classifications.
However, the reviewing authority and level of regulatory scrutiny may vary depending on:
Higher-risk devices may require more detailed documentation where the proposed change is associated with broader modifications affecting safety or performance.
A brand name change should therefore always be evaluated in the context of the complete regulatory status of the device.
Implementing a significant change to approved product information or labelling without following the applicable regulatory procedure can create compliance risks.
Potential consequences may include:
Accurate product identification and labelling are also essential for effective complaint handling, adverse event reporting, traceability, and post-market surveillance.
For this reason, brand-related changes should be managed through a documented regulatory change-control process.
Before changing the brand name of a medical device, organisations should consider the following steps:
Assess the regulatory, quality, labelling, and commercial impact before making any market changes.
Determine whether the proposed modification falls under a major PAC category, an additional brand name process, a labelling change, or another applicable regulatory pathway.
Ensure consistency across labels, IFUs, technical files, quality records, and regulatory submissions.
Trademark registration and brand protection should be considered alongside the regulatory strategy.
Do not introduce the new brand name into the market until the applicable regulatory process has been appropriately completed.
Following approval or completion of the applicable process, update controlled documents and change-control records.
Ensure that historical records can clearly distinguish products marketed under the previous and revised brand names.
CDSCO procedures, online portal categories, guidance documents, and operational requirements may evolve. Companies should regularly monitor official regulatory updates.
Managing a post-approval change requires more than updating product artwork. A proper regulatory assessment is necessary to determine the impact of the proposed change on the existing licence, technical documentation, labelling, and post-market obligations.
MDR Consultants can support manufacturers, importers, and authorised agents with:
Our approach focuses on helping organisations understand the regulatory impact of a proposed change before implementation, reducing the risk of avoidable compliance issues and regulatory delays.
Changing the brand name of a medical device in India should be approached as a regulated post-approval activity rather than a purely commercial exercise.
The Medical Devices Rules, 2017 establish a framework for managing post-approval changes, including substantive changes affecting approved product labelling. CDSCO's operational processes also provide pathways for specific brand-related changes, including matters involving additional brand names.
The precise regulatory route will depend on the nature and scope of the proposed change, device classification, licence type, and whether the product is manufactured domestically or imported.
Manufacturers, importers, and authorised agents should therefore conduct a documented regulatory assessment before implementing a new or additional brand name. Appropriate supporting documentation, regulatory submissions, fees, labelling updates, and quality system changes should be managed in accordance with the applicable MDR 2017 requirements and current CDSCO procedures.
A well-planned approach to post-approval changes helps maintain regulatory compliance, product traceability, patient safety, and uninterrupted market access.
Need assistance with a CDSCO post-approval change or medical device brand name update? MDR Consultants can help you assess the applicable regulatory pathway and manage your compliance requirements effectively.
Last Updated : 01 Sep 2026
The Brand That Promises To Turn Your Business Around!
MDR Consultants excels in guiding medical device companies through global regulatory approvals with tailored solutions, clear communication, and efficient delivery. Their mission-driven approach fosters innovation, compliance, and long-term partnerships built on trust and excellence.
As I observed this company maintains a very good and cooperative environment. "MDR" consultancy is equipped with all modern amenities. They guide you the best. I highly recommend this firm. The entire team is very courteous and helpful. Highly Professional team and the owner is very skilled and humble.
Outstanding expertise! They streamlined our regulatory process, saving us immense time and stress. A truly invaluable partner for medical device compliance.
MDR Consultants have been a reliable partner for our CDSCO registration needs. Their efficient processes and in-depth knowledge of the regulations saved us significant time and resources. We are confident about the quality of their services and their commitment to client satisfaction.
MDR team has consistently delivered quality work, meeting deadlines and exceeding our expectations. We really recommend MDR for regulatory support
My experience with MDR consultants is wonderful. They have in-depth and vast knowledge about their work. They have the team of incredible people. Their commitment towards the client is highly appreciable. I highly recommend to have their services.
MDR IS THE BEST SOLUTION FOR MEDICAL DEVICES CONSULTANCIE THEY PROVIDE ALL THE SOLUTIONS AND PROPER GUIDANCE.AND DELIVER THEIR SERVICES ON TIME .
MDR team has consistently delivered high quality work, meeting deadlines and exceeding our expectations.
It was really a nice experience working with MDR consultancy.They guide you properly with their tranparent work ethics.Honestly MDR consultancy helped me a lot in growing my business.
A very friendly bunch of efficient employees in the team of MDR.A very professional approach towards their job and all my work was done hassle free with least follow up from my side.Keep up great work team MDR!!!!👍👍
The services are top notch , highly recommend for Mr Ashish
Best regulatory services..for medical devices…best in the business
Have a rich experience in the field of consultancy.
Extremely helpful and responsive
Very good experience
Good Services
Appreciable work.
True consultant
Medical Device Regulatory Consultants
37-38, 1st Floor, Near Makhan Bhog, G.T. Road,
Kundli Industrial Area, Delhi NCR, 131028